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Abstract
Saliva, as a biofluid, is inexpensive and non-invasive to obtain, and provides a vital tool to investigate oral health and its
interaction with systemic health conditions. There is growing interest in salivary biomarkers for systemic diseases, notably
cardiovascular disease. Whereas hundreds of genetic loci have been shown to be involved in the regulation of blood
metabolites, leading to significant insights into the pathogenesis of complex human diseases, little is known about the
impact of host genetics on salivary metabolites. Here we report the first genome-wide association study exploring 476
salivary metabolites in 1419 subjects from the TwinsUK cohort (discovery phase), followed by replication in the Study of
Health in Pomerania (SHIP-2) cohort. A total of 14 distinct locus-metabolite associations were identified in the discovery
phase, most of which were replicated in SHIP-2. While only a limited number of the loci that are known to regulate blood
metabolites were also associated with salivary metabolites in our study, we identified several novel saliva-specific
locus-metabolite associations, including associations for the AGMAT (with the metabolites 4-guanidinobutanoate and
beta-guanidinopropanoate), ATP13A5 (with the metabolite creatinine) and DPYS (with the metabolites 3-ureidopropionate
and 3-ureidoisobutyrate) loci. Our study suggests that there may be regulatory pathways of particular relevance to the
salivary metabolome. In addition, some of our findings may have clinical significance, such as the utility of the pyrimidine
(uracil) degradation metabolites in predicting 5-fluorouracil toxicity and the role of the agmatine pathway metabolites as
biomarkers of oral health.
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Introduction
Metabolic reactions pervade every aspect of human physiology,
abnormalities in which underlie a plethora of human diseases
(1). Investigating the genetic underpinnings of population-wide
variation of metabolites can offer novel insights into human
metabolism and diseases, in addition to providing potential
therapeutic targets to modulate metabolite levels. Large-scale
genetic association studies have so far identified hundreds of
loci that regulate the levels of metabolites in blood (2–6) and
to a lesser extent in other biospecimens as well (7–9). Previous
studies have shown that genetic variants on average explain a
greater proportion of trait variance for metabolites compared to
what is generally observed for complex traits (3,4), highlighting
the utility ofmetabolites as intermediate traits for dissecting the
genetics of complex diseases.
Saliva is an abundantly produced biofluid, and it can be
obtained in an inexpensive and non-invasive manner, with-
out the need for healthcare professionals. It is mainly com-
posed of water (>99%) and several other minor constituents
such as mucous, digestive enzymes, cytokines, immunoglobu-
lins, antibacterial peptides, and low molecular weight metabo-
lites (10).
Recent advances in metabolomic profiling allow quantifica-
tion of hundreds ofmetabolites belonging to diverse biochemical
pathways in large population samples (4,11). In 2015, the Human
MetabolomeDatabase (HMDB) incorporated data on the ‘salivary
metabolome’ which included 853 salivary metabolites that were
systematically characterized using a multiplatform approach
(12). Since saliva is separated from the systemic circulation
by just a thin layer of cells, which allows passive and active
exchange of substances (13), it provides a reflection of not just
oral health but the functioning of other organ systems as well
(14). Indeed, a number of studies have previously reported asso-
ciations between oral health and systemic conditions such as
cardiovascular diseases, diabetes, autoimmune diseases,mental
health disorders, and dementia, amongst others (15–19). There-
fore, investigation of salivary metabolites could not only pro-
vide novel biomarkers but also further our understanding of
biological pathways underlying oral as well as general health
conditions.
Herewe report a genome-wide association analysis (based on
1000 Genomes imputed data) for 476 salivary metabolites in the
population-based TwinsUK study, followed by replication in the
population-based Study of Health in Pomerania (SHIP-2) cohort.
Results
Identification of novel genetic loci regulating salivary
metabolite levels
Primary genome-wide discovery analysis in TwinsUK identified
13 metabolites that were significantly associated with genetic
loci after correcting for multiple testing (P<10−10). Furthermore,
when we narrowed our analysis to just the loci that were iden-
tified in the primary stage, one additional metabolite was found
associated (P<10−6). Consequently, a total of 14 distinct locus-
metabolite associations (hereafter, referred to as ‘mQTLs’) were
identified in the discovery phase of our study. The set of signif-
icantly associated variants mapped to 11 distinct genetic loci,
which have been referred to by the name(s) of the overlapping
or the nearest gene(s) (Fig. 1). Three of those loci (AGMAT, SLC2A9
and DPYS) were associated with two metabolites each (Table 1).
In all three instances, the two metabolites regulated by the
same locus were correlated (Pearson’s r2 for the metabolite pairs
ranged between 0.42 and 0.84) (Supplementary Material, Fig. S1).
On the other hand, none of the 14 metabolites that were associ-
ated in our study had more than one significant locus. Quantile-
quantile (QQ) plots for the significantly associated metabolites
are provided in Supplementary Material, Figure S2.
Of the 11 genetic loci that were identified in the discovery
phase, four of them (SLC2A9, DMGDH, FADS2 and ACADS) have
previously been reported in association with blood metabolites
(2,4,5); the remaining seven loci were novel, i.e. they had no
previously known associations with metabolites in blood or any
other biospecimens. For the genetic loci that were associated
with a given metabolite in both saliva and blood, co-localization
analysis showed that a common underlying causal variant at the
locus possibly regulates the metabolite level in both saliva and
blood (P<0.05 for each of the three (out of four) mQTLs for which
summary level data were available).
The AGMAT locus, one of the novel loci identified, was
associated with the metabolites 4-guanidinobutanoate and
beta-guanidinopropanoate. These metabolites are generated as
intermediate products in the polyamine synthesis pathway, the
main site of action for the enzyme agmatinase (encoded by the
AGMAT gene) (20). The most significantly associated variants for
the two metabolites, i.e. rs10927806 and rs6690813, respectively,
are in high LD with one another (r2 = 0.99), suggesting a
shared underlying genetic regulation for the two metabolites
by the AGMAT locus. Similarly, the association between the
ATP13A5 locus and creatinine (a widely used measure of renal
function), observed in our study, has also not been reported
previously. Another interesting novel association that we
identified pertained to themetabolismof the pyrimidine uracil—
the DPYS locus (encodes for the enzyme dihydropyrimidinase,
involved in uracil degradation) was associated with the metabo-
lites 3-ureidopropionate and 3-ureidoisobutyrate (breakdown
products of uracil metabolism). The association between the
TYMS/ENOSF1 locus and ribonate is also intriguing, since it has
previously been shown that ribonate is one of the substrates
for the catalytic activity of reverse thymidylate synthase (rTS),
the protein product of ENOSF1 (21). Therefore, it appears that
ENOSF1, which is the source of anti-sense RNA of TYMS, is
probably the functional genemediating the observed association
of the TYMS/ENOSF1 locus with salivary ribonate. The associa-
tions of the SLC2A9 locus with allantoin, the ABO locus with
N-acetylglucosamine/N-acetylgalactosamine, the UGCG locus
with glycosyl-N-stearoyl-sphinganine, and the MGP locus with
gamma-carboxyglutamate were the remaining mQTLs observed
in our study that have not been reported previously.
Of the 14mQTLs that we identified, it was possible to test the
most significant variant-metabolite pair for nine mQTLs, each
in serum and faecal metabolite data in TwinsUK (metabolites
corresponding to the remaining five mQTLs were not present
in the serum and faecal metabolite datasets). Of them, asso-
ciations for the ATP13A5 and DPYS loci did not replicate in
serum (P>0.05), while none of the associations, barring the
one for the ACADS locus, replicated in the faecal data (P>0.05)
(Supplementary Material, Table S1). Thus, a comparison across
all three biospecimens (for the significantly associated salivary
metabolites which were also measured in serum and faecal
samples in TwinsUK) demonstrates that, in the TwinsUK dataset,
the effects of the ATP13A5 and DPYS loci appear to be specific to
saliva (Supplementary Material, Fig. S3).
For none of the mQTLs did we find any additional inde-
pendent signals at the associated locus after conditioning for
the most significant variant (conditional P>10−5 for all variants
tested at each locus), a findingwhichwas verified by the regional
association plots (Supplementary Material, Fig. S4). The observa-
tion that a single genetic association signal underlies each of the
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Figure 1. Manhattan plot illustrating the findings of the discovery phase (TwinsUK) of the genome-wide association study for salivary metabolites. The red horizontal
line demarcates the study-wide significance threshold of P=10−10. Eleven loci surpassed the study-wide significance threshold. The loci are referred to by the name
(s) of the overlapping or the nearest gene(s).
Table 1. Summary of genetic loci that were significantly associated with salivary metabolite(s) in the discovery phase (TwinsUK)
Locus Index variant Chr Position
(build 37 bp)
Biochemical (metabolite) EA EAF Beta SE P-value
AGMAT rs10927806 1 15909239 4-Guanidinobutanoate C 0.45 0.252 0.037 4.4 × 10−11
rs6690813 1 15861073 Beta-guanidinopropanoate C 0.45 0.708 0.034 4.6 × 10−66
ATP13A5 rs55918334 3 193086314 Creatinine G 0.53 0.305 0.039 3.9 × 10−14
SLC2A9 rs13129697 4 9926967 Urate T 0.72 0.337 0.042 1.3 × 10−14
rs7675964∗ 4 9941434 Allantoin C 0.73 0.239 0.043 4.1 × 10−8
DMGDH rs248386 5 78330227 Dimethylglycine C 0.81 −0.349 0.048 1.1 × 10−12
DPYS rs80274300 8 105470882 3-Ureidopropionate C 0.81 −0.764 0.043 8.1 × 10−54
rs80274300 8 105470882 3-Ureidoisobutyrate C 0.81 −0.482 0.048 5.8 × 10−22
ABO rs201298979 9 136145424 N-acetylglucosamine/N-
acetylgalactosamine
AC 0.77 −0.314 0.046 2.6 × 10−11
UGCG rs10981098 9 114591623 Glycosyl-N-stearoyl-sphinganine T 0.79 −0.308 0.046 4.6 × 10−11
FADS2 rs174564 11 61588305 1-(1-Enyl-palmitoyl)-2-arachidonoyl-GPC A 0.67 0.324 0.039 1.9 × 10−15
ACADS rs34673751 12 121171891 Ethylmalonate G 0.74 −0.539 0.041 5.1 × 10−34
MGP rs5796614 12 15053094 Gamma-carboxyglutamate G 0.60 −0.290 0.038 1.9 × 10−13
TYMS/ENOSF1 rs2790 18 673086 Ribonate A 0.81 0.325 0.049 5.8 × 10−11
Chr=Chromosome; EA=effect allele; EAF=effect allele frequency; SE= standard error. For the primary stage of association analysis in the discovery phase (TwinsUK),
locus-metabolite associations (mQTLs) were identified using a genome-wide and metabolome-wide significance threshold of P< 10−10.
∗This mQTL was identified when the analysis was restricted to only the loci that were identified in the primary stage of association testing (significance threshold of
P< 10−6).
significantly associated metabolites might partly be due to our
lack of power to detect secondary signals at these loci.
The strength of association for the most significant variant-
metabolite pair did not change much on adjusting for periodon-
tal disease (PD) status, for any of the mQTLs (Supplementary
Material, Table S2). Hence, it does not appear that the condition
of oral health, which was ascertained using PD status, has a
significant effect on the associations observed in our study.
Similarly, the most significant variant-metabolite pair for each
of the mQTLs remained significant (P>0.05) on adjusting for
either the smoking status, amount of alcohol intake or BMI
(Supplementary Material, Table S3).
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Table 2. Summary of the discovery phase associations that were tested in the replication study (SHIP-2)
Locus Index variant Chr Biochemical (metabolite) EA Beta SE P-value
AGMAT rs10927806 1 4-Guanidinobutanoate C 0.115 0.044 8.9 × 10−3
ATP13A5 rs55918334 3 Creatinine G 0.239 0.040 2.8 × 10−9
SLC2A9 rs13129697 4 Urate T 0.576 0.045 7.7 × 10−35
rs7675964 4 Allantoin C 0.209 0.049 2.3 × 10−5
DMGDH rs248386 5 Dimethylglycine C −0.336 0.055 1.4 × 10−9
DPYS rs80274300 8 3-Ureidopropionate C −1.035 0.049 3.1 × 10−82
ABOa rs9411378 9 N-acetylglucosamine/N-acetylgalactosamine A 0.032 0.048 0.502
ACADS rs34673751 12 Ethylmalonate G −0.132 0.049 7.3 × 10−3
TYMS/ENOSF1 rs2790 18 Ribonate A 0.137 0.055 0.013
Replication in SHIP-2 could be attempted for 9 of the 14 mQTLs that were identified in the discovery phase (metabolites corresponding to the remaining five mQTLs
were not measured in SHIP-2). For each of these nine mQTLs, the most significant variant-metabolite pair identified in the discovery phase was tested in SHIP-2, using
salivary metabolite data that were not normalized for osmolality (since SHIP-2 saliva samples represented stimulated saliva).
aSince information for the index variant (rs201298979) at the ABO locus was not available in the replication study, a proxy variant (rs9411378) that was in high LD
(r2 = 0.95) with the index variant was used for the replication analysis.
For 8 of the 11 associated loci, it was observed that the
most significant variant demonstrated an eQTL effect on at
least one transcript in one of the tissues in the GTEx database
(no significant eQTL effects were observed for the ATP13A5,
SLCA2A9 and ABO loci) (Supplementary Material, Table S4). In
case of seven of those eight loci (except DPYS), the significant
eQTL effect was observed for the overlapping or the nearest
gene transcript, and for five of those seven loci (AGMAT, FADS2,
DMGDH, TYMS/ENOSF1 and UGCG), the eQTL effect was observed
in one of the gut-related tissues.While eQTL data for transcripts
assayed in the minor salivary glands were available for a small
number of donors (N=97) in the GTEx database, we did not
observe significant eQTL effects in the salivary tissue for any of
the associated loci.
Replication of the discovery phase findings
In SHIP-2,we could attempt replication for 9 of the 14mQTLs that
were identified in the discovery phase (metabolites correspond-
ing to the remaining five mQTLs were not measured in SHIP-
2). In the initial replication analysis, which was performed using
salivary metabolite data that were not normalized for sample
osmolality, eight of the nine discovery phase associations were
replicated (P<0.05), with the direction of effect consistent with
that observed in TwinsUK (Table 2). The association between
the ABO locus and N-acetylglucosamine/N-acetylgalactosamine
was the only finding from the discovery phase that did not
replicate in SHIP-2. When the replication analysis in SHIP-2
was repeated with metabolite data that were normalized for
the sample osmolality, the strength of all the associations was
comparatively reduced (Supplementary Material, Table S5).
Phenotypic associations for salivary metabolites
The majority of the loci associated with salivary metabolites
that were identified in our study have been reported in relation
with GWAS traits, inborn errors of metabolism and/or clini-
cally relevant biochemical pathways (Table 3). We further tested
the salivary metabolites associated with the DPYS, AGMAT and
ATP13A5 loci in relation with specific phenotypes using infor-
mation available in the TwinsUK database (Table 4).
The AGMAT-associated metabolites (4-guanidinobutanoate
and beta-guanidinopropanoate) are generated in the polyamine
synthesis pathway (https://www.genome.jp/kegg-bin/show_
pathway?hsa00330). This pathway also produces the compound
putrescine, which has been implicated in poor oral health and
foul breath (22,23). Consequently, we evaluated the significance
of the AGMAT-associated metabolites in oral health by testing
them with PD status—the levels of both 4-guanidinobutanoate
and beta-guanidinopropanoate were significantly higher in
PD cases compared to controls (P=0.0003 and P=0.0006,
respectively).
Since eGFR (estimated glomerular filtration rate) is calculated
on the basis of serum creatinine, and these two commonly
used measures of renal function are negatively correlated, we
wanted to investigate the association between salivary creati-
nine and eGFR. We observed a similar strong negative relation-
ship between salivary creatinine and eGFR (P=1.6× 10−11),which
is indicative of a homeostasis between creatinine concentrations
in serum and saliva. Furthermore, creatinine is also known to
be a marker of muscle mass and strength (24). We, therefore,
tested salivary creatinine in relation with grip strength (a mea-
sure of muscle strength), which suggested a positive correlation
between them (P=0.01).
Apart from these findings, the remaining phenotypic associ-
ations that we tested were largely negative, as follows:
The enzyme agmatinase (encoded by the AGMAT gene),
which acts on the substrate agmatine, has been implicated in
the pathophysiology of mood disorders (25). Moreover, studies
have also proposed agmatine as a novel neuromodulator (26).
We, therefore, tested the AGMAT-associated metabolites in
relation with a diagnosis of clinical depression or anxiety
disorder, and responses (on a ordinal scale) to questions in the
Hospital Anxiety and Depression Scale (HADS) questionnaire
(27). But, neither analysis showed any significant associations
(Supplementary Material, Table S6).
ATP13A5, the locus that was associated with salivary creati-
nine, belongs to the family of ATPases that regulate the activ-
ity of HMG-CoA reductase (28), the main site of action of the
cholesterol-lowering class of drugs called statins. Statins are
known to cause muscle dysfunction (myopathy) in a small frac-
tion of patients (29). Given that ATP13A5 and statins both act in
the same biochemical pathway, we assessed whether salivary
creatinine is also associated with statin usage, and could there-
fore be used as a biomarker for statin-induced myopathy. There
was, however, no association between salivary creatinine and
statin usage (P=0.22).
5-Fluorouracil (5-FU) is a pyrimidine analogue that is a
commonly used anticancer drug. It is eliminated from the body
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Table 4. Summary of the phenotypes that were tested in relation with specific salivary metabolites
Locus Chr Biochemical (metabolite) Phenotypic association(s) tested
AGMAT 1 4-Guanidinobutanoate 1. Periodontal disease
Beta-guanidinopropanoate 2. Clinical depression or anxiety disorder
ATP13A5 3 Creatinine 1. eGFR (measure of renal function)
2. Grip strength (measure of muscle strength)
3. Statin usage
DPYS 8 3-Ureidopropionate 1. Irritable bowel syndrome (based on the ROME-III criteria)
3-Ureidoisobutyrate
eGFR=effective glomerular filtration rate. Themetabolites that were uniquely associated in saliva, i.e. the ones for which a genetic association had not been previously
reported in blood,were testedwith phenotypes (diseases/traits/adverse drug effects) relating to themetabolite or its associated biochemical pathway, using information
from the TwinsUK database.
via the pyrimidine degradation pathway, and hence, variants
in genes coding for the pyrimidine degradation enzymes
(for instance, DPYS) are known to be associated with the
development of 5-FU toxicity (30), which mainly manifests
as gastrointestinal side effects. Since we could not directly
assess the DPYS-associated metabolites (3-ureidopropionate
and 3-ureidoisobutyrate) in relation to the gastrointestinal side
effects of 5-FU toxicity, we instead used a commonly observed
phenotype of gastrointestinal dysfunction, irritable bowel
syndrome or IBS (ascertained using the ROME-III questionnaire
(31)). For both metabolites, we observed that the levels were
not significantly different in IBS ‘cases’ compared to ‘controls’
(P>0.05, for both metabolites). However, this negative finding
does not negate the possibility that these metabolites could be
of clinical use in predicting 5-FU toxicity.
Discussion
Here we report a genome-wide association analysis of 476
metabolites measured in saliva samples of healthy population-
based studies of European descent. We identified a total of
11 distinct genetic loci that regulate the level of 14 salivary
metabolites, of which three loci were associated with more than
one metabolite each.
The fact that saliva is reflective of the concentration of
biochemicals in blood forms the basis for certain clinical applica-
tions of saliva that others have proposed previously such as ther-
apeutic monitoring of drugs (32), cortisol measurement (33) and
renal function monitoring (34). Using salivary metabolite data,
we replicated associations for certain well-established genetic
loci that are known to regulate the level of blood metabolites.
Thus, our findings add further credence to the notion that, as
biofluids, a certain degree of homeostasis exists between blood
and saliva.
Additionally, we identified some novel associations in
our study, which have expanded our knowledge of genetic
influences on human metabolites. In particular, the association
between theDPYS locus and pyrimidinemetabolites is intriguing
because of its clinical relevance. Mutations in the pyrimidine
catabolism genes such as DPYD (encodes dihydropyrimidine
dehydrogenase) and DPYS (encodes dihydropyrimidinase) have
been linked to inborn errors of metabolism (35,36) as well
as development of severe toxicity to the chemotherapeutic
agent 5-FU (30,37,38). Studies have previously demonstrated
the applicability of salivary measurement of certain pyrimidine
pathway metabolites (uracil and dihydrouracil) for evaluating
5-FU toxicity due to deficient DPYD activity (39). In our
study, variants in the DPYS gene correlated with the levels
of specific pyrimidine metabolites (3-ureidopropionate and 3-
ureidoisobutyrate). Therefore, studies to explore the utility of
salivary measurements of these metabolites as non-invasive
tools for predicting 5-FU toxicity resulting from mutations that
affect DPYS activity are warranted. While we could not test
3-ureidopropionate and 3-ureidoisobutyrate in relation to the
gastrointestinal side effects of 5-FU toxicity, we did not find any
association between thesemetabolites and a phenotype relevant
to gut dysfunction (IBS phenotype).
The other novel finding of note was the association between
theAGMAT locus and themetabolites 4-guanidinobutanoate and
beta-guanidinopropanoate. The AGMAT-associated metabolites
are produced in the polyamine synthesis pathway, which also
generates the compound putrescine that has been implicated
in oral health. Moreover, we found that the AGMAT-associated
metabolites were correlated with PD status, a disease related
to poor oral health. Together, these findings suggest that
the AGMAT-associated metabolites might serve as potential
biomarkers for oral health. On the other hand, though the
agmatine pathway has been previously implicated in mood
disorders, we did not find any association between the AGMAT-
associated metabolites and either symptoms of or a prior
diagnosis of clinical depression or anxiety disorder. Thus,
evidence based on the AGMAT-associated metabolites does
not lend support to the hypothesis regarding a potential link
between pathways involved in maintaining oral health and
regulation of mood (15,18).
The association between the ATP13A5 locus and salivary
creatinine was also noteworthy. While we observed a degree
of homeostasis between salivary and serum creatinine (a com-
monly used measure of renal function), we did not find any
evidence to support our hypothesis of salivary creatinine as a
marker for statin-induced myopathy. There were, however, a
few other novel associations of interest in our study, such as
the one between the MGP locus (known to cause abnormal vas-
cular calcification in patients with cardiovascular disease (40))
and gamma-carboxyglutamate, for which we could not assess
the clinical significance since specific phenotypic information
was not available in sufficient numbers in those with salivary
metabolite data.
While we cannot be certain that the novel genetic associa-
tions which we identified for salivary metabolites relate to the
salivary metabolome alone, we were intrigued to find that these
genetic loci had not been reported in association with blood
metabolites. This suggests that there may be regulatory path-
ways of particular relevance to the salivarymetabolome. Inmost
cases, the gene transcript nearest to or overlapping our novel
genetic loci was expressed in one or more gut-related tissues,
including salivary glands.However, for these loci,we did not find
much evidence for cis-eQTL effects specific to salivary or other
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gut tissues, whereby we could attribute their association with
the respective salivarymetabolite(s) to transcriptional regulation
of overlapping/neighbouring genes.
Interestingly, there is growing evidence to suggest that the
human metabolome is a reflection of an interaction between
the host and the gut microbiome (7,41,42). In the case of the
salivary metabolome, this can be explored by testing the asso-
ciation of the both the compositional and functional attributes
of the salivary metagenome with salivary metabolites. Studies
investigating the gut microbiome have shown a relatively low
overall influence of host genetics on microbiome composition,
but some key taxa have significant heritability (43). If this is
recapitulated in the salivary microbiome, it is possible that the
observed associations between genetic loci and salivarymetabo-
lites could be mediated by the microbiome. Thus, in future
studies with both salivary microbial and metabolite data, it will
be worth investigating whether the salivary metabolites that
were associated in our study correlate with the composition of
the salivary microbiome.
In summary, our study has provided a map of the genetic loci
that influence the salivary metabolome, thus offering insights
into hitherto unknown biological pathways involved in the reg-
ulation of salivarymetabolites. Based onwhat has been observed
for other complex human traits, future studies with larger sam-
ple sizes are expected to uncover additional genetic loci with
much smaller effects on salivary metabolites. While oral health
has been implicated in systemic conditions such as cardiovas-
cular diseases and mental health disorders, the exact mecha-
nisms underlying these associations are far from understood.
Our study identified the potential clinical relevance for a few
salivary metabolites of interest, such as the utility of the pyrimi-
dine (uracil) degradationmetabolites in predicting 5-fluorouracil
toxicity and the role of the agmatine pathway metabolites as
biomarkers of oral health. However, realizing the potential appli-
cation of salivary metabolites as biomarkers of systemic health
conditions would require conducting a more comprehensive
analysis of the salivary metabolome with a wider range of phe-
notypic domains.
Materials and Methods
Discovery phase
Study population. The discovery phase of the studywas conducted
in the TwinsUK cohort, an adult twin registry comprising healthy
volunteers, based at St. Thomas’ Hospital in London (44). Twins
gave fully informed consent under a protocol reviewed by the St.
Thomas’ Hospital Local Research Ethics Committee. Subjects of
European ancestry with available genotype data and for whom
salivary metabolite profiling was done on a fasting state sample
were included in our study (N=1419; mean age=62.2 years; %
females=92.7).
Genotyping, imputation and QC. Subjects were genotyped
in two different batches of approximately the same size,
using two genotyping platforms from Illumina: 300K Duo and
HumanHap610-Quad arrays. Whole genome imputation of the
genotypes was performed using the 1000 genomes reference
haplotypes (45), further details of which are provided in
Moayyeri et al. (44). Stringent QC measures, including minimum
genotyping success rate (>95%), Hardy–Weinberg equilibrium
(P>10−6), minimum MAF (>0.5%) and imputation quality score
(INFO>0.5), retained ∼9.6 million variants for genome-wide
analysis.
Saliva sample collection. Saliva samples were obtained by ask-
ing the fasted volunteer to spit as much saliva as possible into
an empty sterile pot over a period of 10 min. The saliva samples
were immediately refrigerated and then frozen at−80◦C (usually
within 4 h of sample collection) before further processing. Fol-
lowing that, the samples were shipped on dry ice for metabolite
profiling at Metabolon Inc., Durham, USA (see Supplementary
methods (I) for further details on sample processing).
Metabolic profiling of saliva samples. Metabolite concentrations
in the saliva samples were estimated using Ultrahigh Perfor-
mance Liquid Chromatography-Tandem Mass Spectroscopy
(UPLC-MS) i.e. chromatographic separation, followed by full-
scan mass spectroscopy, to record all detectable ions in the
samples (see Supplementary methods (II) for further details).
Based on their unique ion signatures (chromatographic and
mass spectral), 997 distinct metabolites were identified, of
which 823 had known chemical identity at the time of analysis.
The 823 known metabolites were broadly classified into eight
metabolic groups (amino acids, peptides, carbohydrates, energy,
lipids, nucleotides, cofactors and vitamins, and xenobiotics)
as described in the KEGG (kyoto encyclopedia of genes and
genomes) database (46). The eightmetabolic groupswere further
subdivided into 99 distinct biochemical pathways.
Raw metabolite values were normalized for the volume and
osmolality measurement of the saliva samples. The normalized
metabolite values were then log-transformed, and scaled to
uniform mean 0 and standard deviation 1. Of the 823 known
metabolites, 476 were retained for analysis based on the pres-
ence of measurement in more than 80% samples. For these
metabolites, we imputed missing data using the run day min-
imum value for the metabolite, based on the rationale that
missing values representedmetabolite concentrations that were
too low to be detected. The resulting imputed dataset of the 476
metabolites was used for further analysis.
Genome-wide association analysis of salivary metabolites:
(i) Primary genome-wide association analysis
For each of the 476 metabolites, a linear mixed-model was
fitted to test the association between the metabolite (dependent
variable) and genome-wide variants (independent variable).
Age, sex and time of saliva sample collection were included as
covariates in the model. The score test implemented in GEMMA
(47), which utilizes a sample kinship matrix (estimated using a
subset of ∼500000 variants) to account for the twin structure or
relatedness in the TwinsUK data,was used to assess significance
of the associations. A genome-wide and metabolome-wide sig-
nificance cut-off of P<10−10 (corresponding to the conventional
genome-wide significance threshold of 5 × 10−8, corrected
for 476 metabolites) was used to identify significant variant-
metabolite associations. For each locus that was significantly
associated with a metabolite, we reported the variant with the
lowest association P-value.
(ii) Testing loci identified in the primary analysis for additional
metabolite associations
Next, we focused just on the loci that were identified in
the primary stage of association testing to look for additional
variant-metabolite associations for those loci. For each locus
that was identified in the primary analysis, we clumped all
variants located within a 100 Mb block and with LD (r2)>0.2,
to check for additional metabolite associations at a significance
threshold of P<10−6 (corresponding to P=0.05, corrected for
476 metabolites and a prior assumption of about 100 associated
loci).
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(iii) Testing the significantly associated loci using metabolite
data from other biospecimens
For each associated locus, we further assessed the most sig-
nificant variant-metabolite pair by using measurements for the
respective metabolite in serum (4) and faecal samples (7) of the
TwinsUK subjects (provided themetabolitewasmeasured in that
biospecimen). We tested only those serum and faecal samples
that overlappedwith the ones in saliva andwere collectedwithin
5 years of the saliva samples (in order to ensure that, for a
given individual, samples from the different biospecimens being
tested were obtained within a certain period of one another).
Association testing for serum and faecal metabolites was done
using an identical model to that described for the analysis of
salivary metabolites.
In addition, for the locus-metabolite associations that have
been previously reported for blood metabolites, we performed
co-localization analysis using the GSMR/HEIDI method (imple-
mented in GCTA) (48) in order to test whether the associations
in saliva and blood were mediated by a common underlying
signal (pleiotropic effect) or distinct signals at the locus. We
used the metabolomic GWAS summary level data made avail-
able by Shin et al. (4) and Long et al. (5) for the co-localization
analysis.
(iv) Conditional analysis for the significantly associated loci
(a) Detection of secondary association signals
We used approximate conditional analysis, as implemented
in GCTA (49), to test whether any of the associated loci had
multiple distinct, i.e. secondary association signals, at a ‘locus-
wide’ significance threshold of P<10−5. For each associated
locus, all variants that surpassed the study-wide significance
threshold (P<10−10) were conditioned on the most significantly
associated variant at that locus (using the association summary
statistics). For the conditional analysis, we used genotype data
from the complete TwinsUK dataset (N=5654) to model LD pat-
terns between variants.
(b) Adjustment for factors known to affect salivary metabolite
levels
Since the condition of oral health is known to affect salivary
metabolite levels (11), we adjusted the most significant variant-
metabolite pair for each locus-metabolite association for a mea-
sure of oral health that was available in the TwinsUK dataset, i.e.
periodontal disease (PD) status. Self-reported gingival bleeding
and a history of gum disease or tooth mobility were used as
indicators of PD in TwinsUK (50) (270 PD cases; 1083 controls).
Similarly, we also tested the effect of other factors that are
known to affect salivarymetabolite levels, such as smoking, alco-
hol consumption and BMI on the significant locus-metabolite
associations.
Expression quantitative trait locus (eQTL) analysis. We used the
version 7 data release of the Genotype-Tissue Expression (GTEx)
project (accessed 15 April 2019), which was based on RNA-Seq
data obtained from 48 non-diseased tissue sites across ∼1000
individuals, to test whether the most significant variant at each
associated locus had an eQTL effect on transcripts locatedwithin
a 1 Mb window of the variant.
Annotation of associations using reference databases. We
searched the NHGRI GWAS catalogue (accessed 15 April 2019) for
previous disease associations for the significantly associated loci
thatwere identified in our study. For the loci thatwere previously
associatedwith other GWAS traits,we performed co-localization
analysis using the GSMR/HEIDI method (implemented in GCTA)
(48) in order to test whether the associations weremediated by a
common underlying signal (pleiotropic effect) or distinct signals
at the locus. We used publicly available GWAS summary level
data for the co-localization analysis.
We also searched the OMIM database (accessed 15 April 2019)
to check the candidate genes at the associated loci for a causal
link with inborn errors of metabolism.
Moreover, we also queried the HMDB (12) and KEGG (46)
databases to identify biochemical pathways and known disease
associations for the associated metabolites.
Replication phase
The replication phase was performed in the Study of Health
in Pomerania (SHIP-2), a population-based study comprising
European ancestry subjects, conducted in the northeastern area
of Germany. Further details of SHIP-2, including cohort details,
genotyping and imputation, and saliva sample collection are
provided in Supplementary methods (III). Metabolic profiling
for SHIP-2 saliva samples (N=1000) was performed using an
identical process to that described for TwinsUK.
Since themethod of saliva sample collection in SHIP-2 (chew-
ing on a piece of cotton) meant that the sample thus obtained
represented stimulated saliva, normalization of the metabolite
measurements for sample osmolality was not considered nec-
essary. The fact that the salivary osmolality values in SHIP-2
had a much narrower distribution compared to that in TwinsUK
verified our rationale (Supplementary Material, Fig. S5).
For each locus-metabolite association that was identified in
the discovery phase, we tested the most significantly associated
variant using a linear regression model that was fitted on R
(version 3.5.2). Covariates used in the association model were
similar to those used for the discovery phase.
Testing the significantly associated salivary metabolites
with phenotypes of interest
We wanted to test how salivary metabolites that were regu-
lated by genetic loci related to relevant phenotypes. For that,
we selected the metabolites that were uniquely associated in
saliva, i.e. the ones for which a genetic association had not been
previously reported in blood, and tested them with phenotypes
(diseases/traits/adverse drug effects) relating to the metabolite
or its associated biochemical pathway.We obtained the relevant
phenotype information from the TwinsUK database, selecting
one twin per pair (N=1426). The phenotype association analysis
was performed on R (version 3.5.2) by fitting a linear regression
model to test the association between the salivary metabolite
and the disease/trait/adverse drug effect (adjusted for age and
sex).
Web resources
1000 Genomes project: http://www.internationalgenome.org/
Metabolon: https://www.metabolon.com/
GEMMA: http://www.xzlab.org/software.html
KEGG: https://www.genome.jp/kegg/
GCTA: http://cnsgenomics.com/software/gcta/
GTEx: https://gtexportal.org/home/
NHGRI GWAS catalogue: https://www.ebi.ac.uk/gwas/
OMIM: http://omim.org/
HMDB: http://www.hmdb.ca/
LocusZoom: http://locuszoom.org/
UK Biobank GWAS summary data: http://www.nealelab.is/
uk-biobank
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SerummetabolomicGWAS summary data: http://metabolomics.
helmholtzmuenchen.de/gwas/; http://www.hli-opendata.com/
Metabolome/
Supplementary Material
Supplementary material is available at HMG online.
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